Abstract
Background: Direct inhibition of coagulation factor XIa (FXIa) carries a significant promise for developing effective and safe anticoagulants.
Method: In this report, we studied 4-methyl-2-oxo-2H-chromen-7-yl furan-2-carboxylate 1, a coumarin derivative, for direct FXIa inhibition.
Results: This small molecule was found to inhibit FXIa with an IC50 value of 0.77 µM. Coumarin 1 also displayed a moderate-to-high selectivity for FXIa inhibition over other coagulation, digestive, and fibrinolysis serine proteases. Coumarin 1 selectively doubled APTT of human plasma at a concentration of 72 µM. Insights about the structural features that contribute to the unique potential of such small molecule were deduced by profiling similar molecules in PubChem Open Chemistry Database as well as by performing a computational docking exercise.
Conclusion: Overall, chromen-7-yl furan-2-carboxylate 1 is expected to serve as an excellent fragmental lead for further anticoagulant design and development.
Keywords: Factor XIa, anticoagulant, coumarin, active site inhibitor, clotting times, direct inhibition.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor
Volume: 15 Issue: 1
Author(s): Ahmad J. Obaidullah and Rami A. Al-Horani*
Affiliation:
- 1 Drexel Drive, College of Pharmacy, Suite 327, Xavier University of Louisiana, New Orleans, LA 70125,United States
Keywords: Factor XIa, anticoagulant, coumarin, active site inhibitor, clotting times, direct inhibition.
Abstract: Background: Direct inhibition of coagulation factor XIa (FXIa) carries a significant promise for developing effective and safe anticoagulants.
Method: In this report, we studied 4-methyl-2-oxo-2H-chromen-7-yl furan-2-carboxylate 1, a coumarin derivative, for direct FXIa inhibition.
Results: This small molecule was found to inhibit FXIa with an IC50 value of 0.77 µM. Coumarin 1 also displayed a moderate-to-high selectivity for FXIa inhibition over other coagulation, digestive, and fibrinolysis serine proteases. Coumarin 1 selectively doubled APTT of human plasma at a concentration of 72 µM. Insights about the structural features that contribute to the unique potential of such small molecule were deduced by profiling similar molecules in PubChem Open Chemistry Database as well as by performing a computational docking exercise.
Conclusion: Overall, chromen-7-yl furan-2-carboxylate 1 is expected to serve as an excellent fragmental lead for further anticoagulant design and development.
Export Options
About this article
Cite this article as:
Obaidullah J. Ahmad and Al-Horani A. Rami *, Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor, Cardiovascular & Hematological Agents in Medicinal Chemistry 2017; 15 (1) . https://dx.doi.org/10.2174/1871525715666170529093938
DOI https://dx.doi.org/10.2174/1871525715666170529093938 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Abilities of Rice Bran-Derived Antioxidant Phytochemicals for Medical Therapy
Current Topics in Medicinal Chemistry Phytotherapy for the Prevention of Atherosclerosis-Associated Early Cerebral Ischemia
Current Drug Metabolism Untargeted Metabolomics Provides Insight into the Mechanisms Underlying Resistant Hypertension
Current Medicinal Chemistry Covid-19 Susceptibility and Severity Might be Modified by Vitamin D Status: Theoretical and Practical Considerations
Current Respiratory Medicine Reviews Collagen Receptor Integrins: Rising to the Challenge
Current Drug Targets Viral Anti-Inflammatory Reagents: The Potential for Treatment of Arthritic and Vasculitic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Ghrelin and Cardiovascular Diseases
Current Cardiology Reviews The Application of NMR Spectroscopy for the Study of Heart Failure
Current Pharmaceutical Design EDITORIAL [Hot Topic: Biomarkers in Cardiovascular Disease (Guest Editor: Dimitris Tousoulis)]
Current Medicinal Chemistry Integrative Neurochemistry and Neurobiology of Social Recognition and Behavior Analyzed with Respect to CD38-Dependent Brain Oxytocin Secretion
Current Topics in Medicinal Chemistry Reduction in Estimated Glomerular Filtration Rate (eGFR) Results in an Increased Risk of Spontaneous Hemorrhagic Transformation in Patients with Large-artery Atherosclerosis Stroke
Current Neurovascular Research Testosterone Replacement Therapy in Older Male Subjective Memory Complainers: Double-Blind Randomized Crossover Placebo-Controlled Clinical Trial of Physiological Assessment and Safety
CNS & Neurological Disorders - Drug Targets Using Simulation in Clinical Education: Psoriasis Area and Severity Index (PASI) Score Assessment
Current Rheumatology Reviews Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs
Current Pharmaceutical Design Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis
Current Pharmaceutical Design Statins for the Prevention of First or Recurrent Stroke
Current Vascular Pharmacology Sodium-Proton Exchanger Isoform-1: Synthesis of a Potent Inhibitor Labeled with Deuterium and Carbon-14
Current Radiopharmaceuticals Thrombolysis in Ischemic Stroke: Focus on New Treatment Strategies
Recent Patents on Cardiovascular Drug Discovery Obesity in the Cardiovascular Continuum
Current Clinical Pharmacology Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design